Atreca, Inc. (NASDAQ:BCEL) Short Interest Update

Atreca, Inc. (NASDAQ:BCELGet Free Report) was the recipient of a large drop in short interest during the month of March. As of March 15th, there was short interest totalling 148,000 shares, a drop of 45.7% from the February 29th total of 272,700 shares. Based on an average daily trading volume, of 8,350,000 shares, the short-interest ratio is presently 0.0 days.

Atreca Stock Performance

Shares of BCEL opened at $0.08 on Thursday. The firm has a market capitalization of $2.97 million, a price-to-earnings ratio of -0.03 and a beta of 1.17. The business’s fifty day moving average price is $0.24 and its two-hundred day moving average price is $0.24. Atreca has a 52 week low of $0.05 and a 52 week high of $1.35.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of BCEL. Dynamic Technology Lab Private Ltd acquired a new position in shares of Atreca in the 1st quarter valued at $41,000. IHT Wealth Management LLC acquired a new position in shares of Atreca in the 1st quarter valued at $41,000. Advisor Group Holdings Inc. lifted its stake in shares of Atreca by 111.8% in the 1st quarter. Advisor Group Holdings Inc. now owns 16,573 shares of the company’s stock valued at $52,000 after purchasing an additional 8,750 shares during the period. Charles Schwab Investment Management Inc. acquired a new position in shares of Atreca in the 1st quarter valued at $26,000. Finally, Virtu Financial LLC lifted its stake in shares of Atreca by 248.8% in the 1st quarter. Virtu Financial LLC now owns 45,574 shares of the company’s stock valued at $144,000 after purchasing an additional 32,508 shares during the period. 37.47% of the stock is currently owned by institutional investors.

Atreca Company Profile

(Get Free Report)

Atreca, Inc, a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform.

Featured Articles

Receive News & Ratings for Atreca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atreca and related companies with MarketBeat.com's FREE daily email newsletter.